Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “buy” rating restated by JMP Securities in a research report issued on Monday, TipRanks reports. They currently have a $23.00 price target on the biopharmaceutical company’s stock. JMP Securities’ price objective suggests a potential upside of 90.40% from the stock’s previous close.
Other analysts have also recently issued reports about the company. Zacks Investment Research cut Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Marinus Pharmaceuticals in a report on Tuesday, August 17th. Truist Securities lifted their price target on Marinus Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, August 18th. SVB Leerink reissued a “buy” rating on shares of Marinus Pharmaceuticals in a report on Thursday, August 19th. Finally, Truist lifted their price target on Marinus Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, August 18th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $29.11.
MRNS stock traded up $0.02 during mid-day trading on Monday, reaching $12.08. The company had a trading volume of 3,387 shares, compared to its average volume of 265,428. The company has a debt-to-equity ratio of 0.12, a current ratio of 7.24 and a quick ratio of 7.24. The stock has a 50 day simple moving average of $13.43 and a two-hundred day simple moving average of $15.27. The company has a market capitalization of $443.72 million, a price-to-earnings ratio of -4.93 and a beta of 1.21. Marinus Pharmaceuticals has a 52 week low of $10.61 and a 52 week high of $20.04.
Institutional investors and hedge funds have recently modified their holdings of the company. Vectors Research Management LLC bought a new position in shares of Marinus Pharmaceuticals in the 2nd quarter valued at $36,000. Royal Bank of Canada increased its stake in shares of Marinus Pharmaceuticals by 694.1% in the 1st quarter. Royal Bank of Canada now owns 2,438 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 2,131 shares during the last quarter. Citigroup Inc. increased its stake in shares of Marinus Pharmaceuticals by 32.8% in the 2nd quarter. Citigroup Inc. now owns 5,629 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 1,390 shares during the last quarter. Pinz Capital Management LP bought a new stake in Marinus Pharmaceuticals during the 2nd quarter worth $113,000. Finally, Metropolitan Life Insurance Co NY grew its position in Marinus Pharmaceuticals by 154,700.0% during the 2nd quarter. Metropolitan Life Insurance Co NY now owns 10,836 shares of the biopharmaceutical company’s stock worth $194,000 after acquiring an additional 10,829 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
Recommended Story: Different Options Trading Strategies
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.